Business Context and Reporting Period
Company: Techne Corporation (BIO-TECHNE Corp)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter and nine months ended March 31, 2000
Business Overview: The Company operates through two primary subsidiaries: Research and Diagnostic Systems, Inc. (R&D Systems) in Minneapolis and R&D Systems Europe Ltd. in Abingdon, England. Operations are divided into Biotechnology (cytokines, antibodies, assay kits) and Hematology (controls and calibrators) divisions. The Company also holds an equity interest in ChemoCentryx, Inc.
Key Financial Metrics
| Metric | Quarter Ended 3/31/00 | Nine Months Ended 3/31/00 |
|---|---|---|
| Net Sales | $26,776,906 | $76,524,798 |
| Gross Margin | $20,393,973 (76.2%) | $56,167,363 (73.4%) |
| Net Earnings | $7,649,538 | $18,061,840 |
| Diluted EPS | $0.36 | $0.86 |
| Cash & Equivalents | $18,158,301 | $18,158,301 (Balance Sheet) |
| Short-term Investments | $30,623,777 | $30,623,777 (Balance Sheet) |
| Total Debt (Current + Long-term) | $19,953,653 | $19,953,653 (Balance Sheet) |
| Operating Cash Flow (9 Months) | N/A | $26,911,899 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 13% for the quarter and 15% for the nine-month period compared to the prior year. Growth was driven by a $2.2 million increase in protein/antibody sales and a $0.5 million increase in immunoassay kit sales for the quarter.
- Margin Expansion: Gross margins improved significantly to 76.2% for the quarter (up from 69.9%) and 73.4% for the nine months (up from 70.0%). This was attributed to higher sales volume, decreased rent expense following the purchase of the Minneapolis facility, and the sell-through of higher-cost inventory acquired from Genzyme in the prior year.
- Profitability: Earnings before income taxes rose 58% for the quarter and 50% for the nine months. Net earnings increased 69% for the quarter and 55% for the nine months.
- Capital Expenditures: Cash used for fixed assets surged to $27.6 million for the nine months ended March 31, 2000, compared to $3.1 million in the prior year. This includes approximately $21.9 million for the purchase of the Minneapolis facility.
- Debt Structure: The Company incurred $20.4 million in long-term debt (mortgage) to finance the real estate acquisition, whereas no long-term debt was reported in the prior period.
Guidance, Outlook, and Risks
- Capital Requirements: Management expects to finance remaining fiscal 2000 capital additions (approx. $2.6 million) through available funds and operating cash flow. The Company maintains an unsecured line of credit of $750,000 with no current borrowings.
- Stock Repurchase: The Board has authorized the repurchase of up to $10 million of common stock. As of May 8, 2000, $8.75 million worth of shares had been repurchased.
- Dividends: The Company has never paid cash dividends and has no plans to do so in fiscal 2000.
- Risks and Contingencies:
- Market Risk: Exposure to interest rate fluctuations on fixed income investments and foreign currency exchange rate movements (though historically immaterial).
- Operational Risk: Dependence on the acceptance of new biotechnology products and competition in the cytokine research market.
- Legal: Litigation with Streck Laboratories, Inc. was settled during the quarter.
- Y2K: No significant problems related to Y2K were experienced.
Investor Verification Checklist
- Verify the sustainability of the gross margin expansion (76.2%) given the one-time benefit of selling off higher-cost Genzyme inventory.
- Confirm the impact of the new $20.4 million mortgage on future interest expense and cash flow coverage.
- Assess the progress of the $2.6 million in planned capital expenditures for the remainder of fiscal 2000.
- Monitor the performance of the ChemoCentryx, Inc. investment and the associated research grant offsets.
- Review the status of the stock repurchase program relative to the $10 million authorization limit.